Faites connaître cette offre !
Reference : UMR7592-MAXGRE-002
Workplace : PARIS 13
Date of publication : Tuesday, October 5, 2021
Type of Contract : FTC Scientist
Contract Period : 20 months
Expected date of employment : 1 December 2021
Proportion of work : Full time
Remuneration : Between 2743 and 3896€ per month before taxes according to experience
Desired level of education : PhD
Experience required : Indifferent
During early mammalian development, the DNA methylation landscape is profoundly remodeled. The candidate will explore non-conventional ways that DNA methylation can impact gene regulation and genome regulation during this period. In order to carry this out, we will utilize a mouse embryonic stem cell differentiation model.
Cell culture : Mouse embryonic stem cell culture and differentiation, CRISPR-mediated genome and epigenome editing.
Molecular biology: DNA methylation and chromatin profiling. Chromosome conformation capture
Bioinformatics: Analysis of generated NGS data sets
We are looking for independent researchers with strong communication skills, are open minded, and generous with their colleagues. A strong background in molecular biology techniques is required. Experience with mammalian cell culture would be helpful, but is not required. A computational background is encouraged in the candidates.
The position is open in the team of Maxim Greenberg (Chromatin Dynamics in Mammalian Development), and will be supported by a joint ANR grant shared with Pierre-Antoine Defossez (Epigenetics and Cell Fate Unit, Paris, CNRS UMR7216) and Salvatore Spicuglia (TAGC, Marseille, INSERM U1090)
The research is carried out within the Institut Jacques Monod, which is a joint CNRS - Université de Paris research unit with approximately 350 employees. The IJM is part of the INSB and is housed in a recently constructed University building on the Paris Left Bank campus located in the 13th arrondissement of Paris and accessible by all means of transport (Metro 14, RER C, T3 tramway, bus 62 and 89...)
Constraints and risks
We talk about it on Twitter!